Page 2 Dkt: 103.014US3

## **IN THE CLAIMS**

Please amend the claims as follows:

1. (Currently Amended) A method of reducing the viability of leukemia cells in a mammal sensitive to a 1-(R) compound of formula (II):

$$\begin{array}{c|c}
R^5 & R^4 \\
R^7 & R^1 & Y-Z
\end{array}$$
(II)

wherein R<sup>1</sup> is lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl or benzyl, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are the same or different and are each hydrogen or lower alkyl; R<sup>6</sup> is hydrogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R<sup>7</sup> is hydrogen, lower alkyl or lower alkenyl; X is oxy; Y is carbonyl or (C<sub>1</sub>. C<sub>3</sub>)alkyl(CO), wherein each alkyl is substituted with 0-2 (C<sub>1</sub>-C<sub>4</sub>) alkyl, and Z is hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino or phenylamino;

comprising administering from about 50 mg to about 5000 mg of the (R)-compound of formula (II); or a salt thereof to a human cancer patient afflicted with a leukemia.

2. (Original) A method of increasing the susceptibility of leukemia cells in a mammal to a chemotherapeutic agent comprising contacting the cells with from about 50 mg to about 5000 mg of a compound of formula (II):

$$\begin{array}{c|c}
R^5 & R^4 \\
R^7 & R^1 & Y-Z
\end{array}$$
(II)

Page 3 Dkt: 103.014US3

wherein R<sup>1</sup> is lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl or benzyl, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are the same or different and are each hydrogen or lower alkyl; R<sup>6</sup> is hydrogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R<sup>7</sup> is hydrogen, lower alkyl or lower alkenyl; X is oxy; Y is carbonyl or (C<sub>1</sub>-C<sub>3</sub>)alkyl(CO), wherein each alkyl is substituted with 0-2 (C<sub>1</sub>-C<sub>4</sub>) alkyl, and Z is hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino or phenylamino; or a pharmaceutically acceptable salt thereof.

- 3. (Currently Amended) The method of claim 1, comprising administering from about 100 mg to about 2500 mg wherein concentration of the compound of formula (II) about 100 mg to about 2500 mg.
- 4. (Currently Amended) The method of claim 2, comprising administering from about 100 mg to about 2500 mg wherein concentration of the compound of formula (II) about 100 mg to about 2500 mg.
- 5. (Currently Amended) The method of claim 1 wherein the compound of formula (II) is administered in a single dose.
- 6. (Currently Amended) The method of claim 2 wherein the compound of formula (II) is administered in a single dose.
- 7. (Currently Amended) The method of claim 1 wherein the compound of formula (II) is administered in divided doses.
- 8. (Currently Amended) The method of claim 2 wherein the compound of formula (II) is administered in divided doses.

Title: USE OF ETODOLAC FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

- 9. (Currently Amended) The method of claim 1 <u>further comprising administering wherein</u> the <u>compound of formula (II) to achieve a plasma</u> concentration of the <u>compound of formula (II) is from about 200 μM to about 1000 μM 400 μM</u>.
- 10. (Currently Amended) The method of elaim-1 claim 2 further comprising administering wherein the compound of formula (II) to achieve a plasma concentration of the compound of formula (II) is from about 200  $\mu$ M to about 1000  $\mu$ M 400  $\mu$ M.
- 11. (Original) The method of claim 1 wherein the leukemia is chronic lymphocytic leukemia.
- 12. (Original) The method of claim 2 wherein the leukemia is chronic lymphocytic leukemia.
- 13. (Currently Amended) The method of claim 1 wherein the a mammal is a human.
- 14. (Currently Amended) The method of claim 2 wherein the a mammal is a human.
- 15. (Cancelled) The method of claim 14 wherein the mammal is undergoing treatment with a chemotherapeutic agent.
- 16. (Original) The method of claim 1 wherein the compound of formula (II) or the salt thereof is administered orally.
- 17. (Original) The method of claim 2 wherein the compound of formula (II) or the salt thereof is administered orally:
- 18. (Original) The method of claim 1 wherein the compound of formula (II) is R(-)-etodolac.
- 19. (Original) The method of claim 2 wherein the compound of formula (II) is R(-)-etodolac.

AMENDMENT AND RESPONSE UNDER 37 CFR § 1.111

Serial Number: 10/753,665

Filing Date: January 8, 2004
Title: USE OF ETODOLAC FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

Page 5 Dkt: 103.014US3

20. (Cancelled) The method of claim 15 wherein compound of formula (II) is administered in combination with the chemotherapeutic agent.